NCT07270146

Effectiveness and Safety of Guilu Erxian Oral Liquid in the Treatment of Oligozoospermia and Asthenospermia With Syndrome of Shen (Kidney) Essence Deficiency

A Multicenter, Randomized, Double-blind, Positive Drug Controlled Clinical Trial on the Efficacy and Safety of Guilu Erxian Oral Liquid in the Treatment of Oligozoospermia and Asthenospermia With Syndrome of Shen (Kidney) Essence Deficiency

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 360 (actual)
• Sponsor: DongE E Jiao Coporation Limited · Industry
• Sex: Male
• Age: 22 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

The main function of Guilu Erxian Oral Liquid is to warm the shen (kindney) and replenish essence. It is used for chronic shen (kindney) deficiency, waist and knee weakness, spermatorrhea and impotence. The treatment of deficiency of kidney essence and asthenospermia is to invigorate the shen (kindney) and replenish the essence, nourish the shen (kindney) and assist the essence. The idea of combining traditional Chinese and western medicine is to move the yang and calm the yin, and traditional Chinese medicine is mainly to invigorate the shen (kindney) and replenish the essence. In order to better provide the basis for clinical medication and meet the treatment needs of oligozoospermia and asthenospermia, this trial is intended to evaluate the effectiveness and safety of Guilu Erxian oral liquid in treating oligozoospermia and asthenospermia with Syndrome of Shen (Kidney) Essence Deficiency subjects.

Conditions

• Mild and Moderate Oligozoospermia Asthenospermia or Oligoasthenospermia and the Syndrome Differentiation Type is Shen (Kidney) Essence Deficiency

Interventions

Type	Name	Description
DRUG	Guilu Erxian Oral Liquid	Guilu Erxian Oral Liquid+Wuzi Yanzong Oral Liquid Simulator
DRUG	Wuzi Yanzong oral liquid	Wuzi Yanzong oral liquid+Guilu Erxian oral liquid simulator

Timeline

• Start date: 2022-10-08
• Primary completion: 2025-02-10
• Completion: 2025-02-10
• First posted: 2025-12-08
• Last updated: 2025-12-08

Locations

1 site across 1 country: China